An observational study in Spondylolisthesis, Grade 1, sponsored by Research Source. Enrolling by invitation at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Research Source · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Spondylolisthesis with a site in United States — 14 open to participants now, 18 under way, none of them phase 3. Spondylolisthesis · United States.
Among the 102 studies in Spondylolisthesis with a site in United States, this one is the 28th largest by planned enrollment of the 38 observational ones that give a count, is one of 5 that started in 2024, is one of 38 observational ones, reaches primary completion later than 3 of the 17 other live ones, and was the 98th registered.
227 studies on the registry are indexed under Spondylolisthesis; 43 are open to participants now.
Browse Spondylolisthesis studies →14 of the 102 studies in Spondylolisthesis with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 12–18
Spinal Simplicity LLC · Sites in United States
Ages 18+
Alphatec Spine, Inc. · Sites in United States
Ages 18+
Bioventus LLC · Sites in United States
Ages 21–80
Francis Farhadi · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Spondylolisthesis studies recruiting now, 11 (41%) set no upper age limit and 8 (30%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 22 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 5 · Phase 4 8
First in 2000; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 108 across 79 observational studies indexed under Spondylolisthesis.
Median enrollment 50 across the 64 interventional studies, 114 across the 38 observational. Of the 67 that completed or were terminated, 20 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 102 have an industry lead sponsor. The 10 most frequent:
Research Source is the lead sponsor of 8 studies on the registry; 7 are open to participants now.
Research Source has 1 study filed under Spondylolisthesis — fewer than ten, so there is no comparison to draw.
6 of the studies in Spondylolisthesis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691062Twin Cities Spine CenterTitanium vs. PEEK Fusion Devices in 1 Level TLIF | 2027-01-11 |
| NCT05029726John O'TooleRegional Anesthesia in Minimally Invasive Lumbar Spine Surgery | 2027-02-01 |
| NCT06093477Stanford UniversityStudying Melatonin and Recovery in Teens | 2027-06-01 |
| NCT04204135Rush University Medical CenterThe Course of Hip Flexion Weakness Following LLIF or ALIF | 2027-09-04 |
| NCT07766824National University of Natural MedicineEvaluation of an Online Peri-operative Health Education Platform for Patients Undergoing Spine Surgery: Ready Set Recover | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 102 studies in Spondylolisthesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the radiographic and clinical outcomes of spinal fusion following use of Allosync Expand and autograft bone graft.
This is a single site, prospective study with patients selected as study subjects from the Investigator's standard patient population who fulfill the Inclusion/Exclusion Criteria and agree to participate in the study. The study surgery is standard of care, with patients identified as requiring surgery prior to enrollment. The study surgery is lumbar posterior fixation with supplemental posterolateral fusion at from 1 to 3 levels. One side of the posterolateral fusion will be Allosync Expand (utilizing the BMA Angel kit to hydrate) and the other side to autograft bone (control).
A patient who meets all inclusion criteria and none exclusion criteria will be enrolled in the study. A patient is considered enrolled upon placement of the Allosync Expand during the surgical procedure. If the surgeon decides intra-operatively not to utilize Allosync Expand, the patient will be considered a screen failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must have a documented diagnosis of spondylolisthesis up to Grade I. and have confirmed back and/or radicular pain with associated spinal stenosis as documented by conditions such as:
Subject presents with one or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled patients will received Allosync Expand at 1-3 contiguous levels (L1-S1).
Device: Allosync Expand
Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)
Also known as: Acceell Family of Products (Accell DBM 100, Accell TBM, A2i, and Accell Connexus)
Lumbar fusion rate assessed via CT
Lumbar fusion rate assessed via CT at 12 months post surgery
Time frame: 12 months post surgery
Clinical outcome via neck visual analog scale (VAS)
Standard of care patient reported neck visual analog scale (VAS) will be used to evaluate patient pain. On a scale of 0 to 10 with a score of 0 being no pain and a score of 10 being worst pain. A low score means a better clinical outcome. A high score means a worse clinical outcome.
Time frame: 12 months post surgery
Clinical outcome via Overall Quality of Life (EQ-5D) EuroQol Research Foundation
Standard of care patient reported Overall Quality of Life (EQ-5D) EuroQol Research Foundation will be used to evaluate patient quality of life. On a scale of 3 levels: no problems, some problems, and extreme problems. With a score of "no problems" being no interference in quality of life and a score of "extreme problems" being a high interference in quality of life. "No problems" responses means a better clinical outcome. "Extreme problems" responses mean a worse clinical outcome.
Time frame: 12 months post surgery
Clinical outcome via PROMIS short form - Physical Evaluation
Standard of care patient reported PROMIS short form - Physical Evaluation will be used to evaluate patient physical function. On a scale of 5 levels: without any difficulty, with a little difficulty, with some difficulty, with much difficulty, and unable to do. With a score of "without any difficulty" being no interference in physical function and a score of "unable to do" being high interference in physical function. "Without any difficulty" means a better clinical outcome. "Unable to do" means a worse clinical outcome.
Time frame: 12 months post surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for May 2026, 23 months after the start.
Of 37 observational studies under Spondylolisthesis, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 93. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research Source